Astellas Pharma said that the FDA has accepted for review a revised application for its complement C5 inhibitor Izervay (avacincaptad pegol) that aims to add positive two-year clinical… read more.
Transitioning from diapers to the toilet is a major step for young children — and their parents. Now a new report shines a light on just how bumpy… read more.
Nearly one-third of the nation’s K-12 U.S. public schools mandate mental health screening for students, with most offering in-person treatment or referral to a community mental health professional… read more.
Eisai Co., Ltd. announced that the company will present the latest findings from its robust Alzheimer’s disease (AD) pipeline and research, including our dual-acting, anti-amyloid beta (Aβ) protofibril… read more.
Eisai Co., Ltd. and Biogen Inc. announced that the European Commission (EC) has granted the amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) Marketing Authorization (MA) in the European Union… read more.
Each year, numerous patients worldwide require surgical interventions that could benefit from the precision and safety offered by surgical robots. The standard approach for complex surgeries often involves… read more.
Millions worldwide suffer from UV-induced skin damage, photoaging, and skin cancer annually. Current sunscreen efficacy testing relies on minimal erythema dose (MED) and minimal persistent pigment dose (MPPD);… read more.
Biogen Inc. anounced upcoming scientific presentations at the 2025 Alzheimer’s Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMB® (lecanemab) will include 48-month results… read more.
Kite, a Gilead Company announced results from the primary analysis of ZUMA-3, a global, multicenter, single-arm, open-label Phase 1/II study evaluating its chimeric antigen receptor (CAR) T-cell therapy… read more.
What if we could prevent people from developing obesity? The World Obesity Federation expects more than half the global population to develop overweight or obesity by 2035. However,… read more.
Wearable healthcare devices, such as glucose monitors and heart monitors, are popular due to their ability to gather real-time data that supports users’ health and safety. However, despite… read more.
NICE is unable to make a recommendation on tislelizumab (Tevimbra) in combination for untreated advanced non-small-cell lung cancer in adults. This is because the company did not provide… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
